Table 3. Tumor response in patients received chemotherapy according to RECIST.
| Pemetrexed-based | Non-pemetrexed based | P value | ||
|---|---|---|---|---|
| First-line treatment | n = 28 | n = 19 | ||
| CR | 0 | 0 | ||
| PR | 15 | 7 | ||
| SD | 8 | 5 | ||
| PD | 5 | 7 | ||
| NE | 0 | 0 | ||
| ORR | 15 (53.6%) | 7 (36.8%) | 0.259 | |
| DCR | 23 (82.1%) | 12 (63.2%) | 0.143 | |
| ≥ Second-line treatment | n = 21 | n = 25 | ||
| CR | 0 | 0 | ||
| PR | 5 | 4 | ||
| SD | 7 | 5 | ||
| PD | 7 | 13 | ||
| NE | 2 | 3 | ||
| ORR | 5 (23.8%) | 4 (16.0%) | 0.770 | |
| DCR | 12 (57.1%) | 9 (36.0%) | 0.152 |
CR, complete response; PR, partial response; SD, stable disease; PD: progression disease; NE, Not evaluable; ORR: overall response rate; DCR: disease control response.